S2CID 5772424
Subcutaneous Injection Advantages Easy to administer Once a person is trained, they can easily inject themselves in the stomach or thigh area
Specifically, cagrilintide is thought to: slow gastric emptying (the movement of food out of the stomach) suppress the release of glucagon after eating to reduce blood glucose levels activate centers in the brain associated with appetite and reward to reduce how much you eat What Is CagriSema
Residual confounding cant be ruled out
1 In adults with obesity, along with diet and exercise, A well-studied safety profile for adults with obesity: Pooled safety data from 2 weight-management clinical trials evaluating Wegovy HD 7.2 mg 1 Wegovy HD (semaglutide) injection 7.2 mg had a safety profile consistent with Wegovy 2.4 mg 1,3 5% of patients with Wegovy HD 7.2 mg pen, 5% of patients with Wegovy 2.4 mg pen, and 2% of patients with placebo permanently discontinued as a result of adverse reactions 1 The most common adverse reactions leading to discontinuation were gastrointestinal disorders: 3% of patients with Wegovy HD 7.2 mg pen, 3% of patients with Wegovy 2.4 mg pen, and 0.3% of patients with placebo 1 Includes allodynia, burning sensation, dysesthesia, hyperesthesia, hyperpathia, pain of skin, paresthesia, sensitive skin, skin burning sensation, skin discomfort, and skin sensitization